Trishomocubanes: Novel σ ligands modulate cocaine-induced behavioural effects

European Journal of Pharmacology

Volumn 555, Issue 1, 2007, Pages 37-42

  Liu, Xiang ^a   Banister, Samuel D ^b   Christie, MacDonald J ^c   Banati, Richard ^c   Meikle, Steve ^c   Coster, Mark J ^b   Kassiou, Michael ^b,c  

^a University of Sydney   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

receptors; Cocaine; Polycyclic; Trishomocubanes

Indexed keywords

CENTRAL STIMULANT AGENT; COCAINE; DOPAMINE TRANSPORTER; N (3' FLUOROPHENYL)ETHYL 4 AZAHEXACYCLO[5.4.1.0 2,6 .0 3,10 .0 5,9 .0 8,11 ]DODECAN 3 OL; N (3' FLUOROPHENYL)METHYL 4 AZAHEXACYCLO[5.4.1.0 2,6 .0 3,10 .0 5,9 .0 8,11 ]DODECAN 3 OL; NORADRENALIN TRANSPORTER; OPIATE ANTAGONIST; RECEPTOR SUBTYPE; SEROTONIN TRANSPORTER; SIGMA OPIATE RECEPTOR; SODIUM CHLORIDE; TRISHOMOCUBANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DEPRESSION; DISCRIMINATION LEARNING; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; LOCOMOTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; BRIDGED COMPOUNDS; COCAINE; DISCRIMINATION LEARNING; DOPAMINE UPTAKE INHIBITORS; LIGANDS; MALE; MICE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA;

EID: 33845723629     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.10.020     Document Type: Article

References (32)

1. Cao J., Kulkarni S.S., Husbands S.M., Bowen W.D., Williams W., Kopajtic T., Katz J.L., George C., and Newman A.H. Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4′-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. J. Med. Chem. 46 (2003) 2589-2598
2. 3H] dopamine. Life Sci. 42 (1988) 2553-2559
3. 3H]dopamine release from rat striatal slices by sigma receptor ligands. J. Pharmacol. Exp. Ther. 271 (1994) 212-219
4. Hayashi T., and Su T.P. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. Life Sci. 77 (2005) 1612-1624
5. Hellewell S.B., and Bowen W.D. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 527 (1990) 244-253
6. Itzhak Y., and Ali S.F. Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain. Ann. N.Y. Acad. Sci. 844 (1998) 245-251
7. Izenwasser S., Newman A.H., and Katz J.L. Cocaine and several sigma receptor ligands inhibit dopamine uptake in rat caudate-putamen. Eur. J. Pharmacol. 243 (1993) 201-205
8. Katz J.L., Libby T.A., Kopajtic T., Husbands S.M., and Newman A.H. Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur. J. Pharmacol. 468 (2003) 109-119
9. Kuhar M.J. Molecular pharmacology of cocaine: a dopamine hypothesis and its implications. Ciba Found. Symp. 166 (1992) 81-89
10. Liu X., Kassiou M., Christie M.J., and Hambley T.W. Trishomocubanes: requirements for α receptor binding and subtype selectivity. Aust. J. Chem. 54 (2001) 31-36
11. 3H]dopamine release. Eur. J. Pharmacol. 422 (2001) 39-45
12. 123I]iodobenzamide in vivo in the rat brain. Med. Chem. 1 (2005) 31-38
13. Liu Y., Chen G.D., Lerner M.R., Brackett D.J., and Matsumoto R.R. Cocaine up-regulates Fra-2 and sigma-1 receptor gene and protein expression in brain regions involved in addiction and reward. J. Pharmacol. Exp. Ther. 314 (2005) 770-779
14. Martin W.R., Eades C.G., Thompson J.A., Happler R.E., and Gilbert P. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
15. Matsumoto R.R., and Mack A.L. (+/-)-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur. J. Pharmacol. 417 (2001) R1-R2
16. Matsumoto R.R., McCracken K.A., Pouw B., Miller J., Bowen W.D., Williams W., and De Costa B.R. N-Alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur. J. Pharmacol. 411 (2001) 261-273
17. Matsumoto R.R., McCracken K.A., Pouw B., Zhang Y., and Bowen W.D. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 42 (2002) 1043-1055
18. Matsumoto R.R., Liu Y., Lerner M., Howard E.W., and Brackett D.J. Sigma receptors: potential medications development target for anti-cocaine agents. Eur. J. Pharmacol. 469 (2003) 1-12
19. Matsumoto R.R., Gilmore D.L., Pouw B., Bowen W.D., Williams W., Kausar A., and Coop A. Novel analogs of the sigma receptor ligand BD1008 attenuate cocaine-induced toxicity in mice. Eur. J. Pharmacol. 492 (2004) 21-26
20. McCracken K.A., Bowen W.D., and Matsumoto R.R. Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur. J. Pharmacol. 365 (1999) 35-38
21. Menkel M., Terry P., Pontecorvo M., Katz J.L., and Witkin J.M. Selective sigma ligands block stimulant effects of cocaine. Eur. J. Pharmacol. 201 (1991) 251-252
22. 3H]1,3-di-O-tolylguanidine (DTG) on σ binding sites in rat and guinea pig brain membranes: novel σ-2 selective trishomocubanes. Eur. J. Pharmacol. 311 (1996) 233-240
23. Reith M.E., Meisler B.E., Sershen H., and Lajtha A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol. 35 (1986) 1123-1129
24. Ritz M.C., and George F.R. Cocaine toxicity: concurrent influence of dopaminergic, muscarinic and sigma receptors in mediating cocaine-induced lethality. Psychopharmacology (Berl.) 129 (1997) 311-321
25. Romieu P., Martin-Fardon R., and Maurice T. Involvement of the signal receptor in the cocaine-induced conditioned place preference. NeuroReport 11 (2000) 2885-2888
26. Romieu P., Martin-Fardon R., Bowen W.D., and Maurice T. Sigma 1 receptor-related neuroactive steroids modulate cocaine-induced reward. J. Neurosci. 23 (2003) 3572-3576
27. Sharkey J., Glen K.A., Wolfe S., and Kuhar M.J. Cocaine binding at sigma receptors. Eur. J. Pharmacol. 149 (1988) 171-174
28. Skuza G. Effect of sigma ligands on the cocaine-induced convulsions in mice. Pol. J. Pharmacol. 51 (1999) 477-483
29. Ujike H., Tsuchida K., Akiyama K., and Otsuki S. Supersensitivity of sigma receptors after repeated administration of cocaine. Life Sci. 51 (1992) PL31-PL36
30. Ujike H., Kuroda S., and Otsuki S. Sigma receptor antagonists block the development of sensitization to cocaine. Eur. J. Pharmacol. 296 (1996) 123-128
31. 3H] dopamine release from rat pheochromocytoma (PC12) cells by sigma type 2 receptors. J. Pharmacol. Exp. Ther. 289 (1999) 278-284
32. Witkin J.M., Terry P., Menkel M., Hickey P., Pontecorvo M., Ferkany J., and Katz J.L. Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J. Pharmacol. Exp. Ther. 266 (1993) 473-482